Fig. 3
From: CRO-67 has anti-cancer activity in pancreatic tumor cells and stromal cancer-associated fibroblasts
CRO-67 is the active enantiomer of CRO-05 that decreased viability and increased apoptosis in PDAC and CAF cells. MiaPaCa-2 (N = 3) and primary patient-derived CAFs isolated from N = 3 PDAC patients were treated with vehicle control, CRO-05, CRO-67 and CRO-68 (1.5 μM) and analyzed 24 h post-treatment. (a, b) Cell viability was measured by counting live cells via trypan blue exclusion assay. CRO-05 and CRO-67 treated MiaPaCa-2 cells and patient-derived CAFs demonstrated a reduction in cell viability while CRO-68 treated cells showed no change. (c, d) Apoptosis was measured by flow cytometry for Annexin V/DAPI. MiaPaCa-2 (N = 3) and CAFs (N = 3) demonstrated an increase in apoptosis 24 h post-treatment with CRO-05 and CRO-67, but no change when treated with CRO-68. Bars represent mean ± SD (N = 3). Asterisks indicate significance as assessed by one-way ANOVA, and Bonferroni’s multiple comparisons tests (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001).
